QUOTE AND NEWS
Business Wire  Nov 23  Comment 
Array BioPharma Inc. (Nasdaq: ARRY) today announced that its Chief Executive Officer, Robert E. Conway, will speak at the 21st Annual Piper Jaffray Healthcare Conference on December 1 in New York City. The public is welcome to participate in the
StreetInsider.com  Nov 5  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Upgrades/UBS+Upgrades+Array+BioPharma+%28ARRY%29+to+Buy+/5078365.html for the full story.
StreetInsider.com  Nov 2  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Earnings/Array+BioPharma+%28ARRY%29+Reports+Q1+Loss+of+%240.52%2C+Beats+by+3c/5065927.html for the full story.
Business Wire  Nov 2  Comment 
Array BioPharma Inc. (Nasdaq: ARRY) today reported financial results for the first quarter of fiscal 2010. Array reported revenue of $7.9 million for the first quarter of fiscal 2010, compared to revenue of $5.7 million for the same period in fiscal
Business Wire  Oct 28  Comment 
Array BioPharma Inc. (Nasdaq: ARRY) will report financial results for the first quarter of fiscal 2010 on Monday, November 2, 2009, and will hold a conference call on Tuesday, November 3, 2009 at 9:00 a.m. eastern time to discuss these results.
Business Wire  Sep 15  Comment 
Array BioPharma Inc. (Nasdaq: ARRY) today announced that its Chief Executive Officer, Robert E. Conway, will speak at the UBS Global Life Sciences Conference on September 21 in New York City. The public is welcome to participate in the conference
Stock Blog Hub  Sep 8  Comment 
Last week, Array BioPharma (ARRY) announced that its most advanced, wholly-owned MEK inhibitor, ARRY-162, which was being developed to treat rheumatoid arthritis patients, failed to achieve a better response than placebo in a mid-stage...
newratings.com  Sep 8  Comment 
NEW YORK, September 8 (newratings.com) - Analysts at UBS downgrade Array Biopharma (ticker: ARRY) from "buy" to "neutral." [more]
Suggest a News Source
Topic
Top news source/blog that we're missing
Why do you recommend this news source?
Close 
Thanks for your suggestion!
 
 
TOP CONTRIBUTORS
ARRY AT A GLANCE
P/E -0.759 
EV/EBITDA -2.30 
ROA -87.1%VERY LOW
ROE -569.6%VERY LOW
Debt to Equity -2.33 
Current Ratio 1.75AVG
Interest Coverage Ratio -10.5AVG
 
 
 
 
 
 
 
 

Array BioPharma (ARRY) is creating the next generation of orally active drugs by utilizing the latest advances in chemistry, biology, and informatics. The company's discovery platform integrates various research technologies, including proprietary computational software, lead optimization, library screening, state-of-the-art protein x-ray crystallography, and extensive safety profiling. Array offers these Contract Research Services to a number of leading biotechnology and pharmaceutical companies such as Eli Lilly, Roche, Amgen, Genentech, AstraZeneca, Celgene, Trimeris, ICOS, Ono Pharmaceuticals, and InterMune. Array collaborates with these companies to design, create, and optimize drug candidates across a broad range of therapeutic areas. Array also possesses its own In-house Research and Development (R&D) Programs, and drug development pipeline. The company focuses primarily in areas where there is a significant unmet medical need. Current programs in cancer and inflammatory diseases include several promising small molecule drugs that regulate targets in therapeutically important disease pathways. Array BioPharma currently employs approximately 335 professionals, including roughly 255 scientists. It was founded in 1998 and is headquartered in Boulder, CO.

In June 2006, Array BioPharma Inc. completed a series of agreements with its existing landlords for its Boulder and Longmont, Colorado facilities and with BioMed Realty Trust, Inc., a real estate investment trust, under which Array will assign options to purchase its facilities to BioMed. BioMed will purchase the Boulder and Longmont facilities and then lease those facilities to Array through 2016. The transaction was completed in August of 2006, and Array received approximately $32 million in net additional cash. Array will keep its headquarters in Boulder and continue operating its 228,000 square foot research facilities in Boulder and Longmont, Colorado. In August 2005, Array announced an amendment to its Longmont facility lease, under which Array received the options to expand and to purchase the facility. At that time, Array anticipated that it would consolidate all operations in Longmont. In recent negotiations with the owner of the Boulder facility, however, Array was able to obtain improved terms and an option to purchase the buildings.




References

Wikinvest © 2006, 2007, 2008, 2009. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki